Company profile: 10x Genomics
1.1 - Company Overview
Company description
- Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
Products and services
- Chromium Single Cell Gene Expression: Delivers single-cell–resolution transcriptomic profiling, offering multiomic analysis of gene expression with cell surface proteins and CRISPR perturbations
- Chromium Single Cell Immune Profiling: Offers multiomic, single-cell analysis of the immune system, capturing gene expression, cell surface proteins, and full-length paired BCR and TCR sequences
- Visium HD Spatial Gene Expression: Produces single cell-scale spatial transcriptomics using probe-based chemistry and continuous tissue coverage via Visium CytAssist-enabled workflow to map whole transcriptomes within tissue sections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 10x Genomics
AutoGenomics
HQ: United States
Website
- Description: Provider of automated microarray-based multiplex molecular diagnostic platforms and genetic testing tools, including INFINITI System, INFINITI PLUS Analyzer, INFINITI High Throughput System, proprietary BioFilmChip microarrays, and assays such as AvertD for opioid use disorder risk and Factor II-V Leiden for thrombophilia, for disease signature assessment in women's health, cancer and personalized medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AutoGenomics company profile →
Toma Biosciences
HQ: United States
Website
- Description: Provider of DNA-based cancer testing technology, developed and provided by a biotechnology company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Toma Biosciences company profile →
Genoway
HQ: France
Website
- Description: Provider of genetically modified mouse, rat, and cell line models for preclinical research in biopharma and academia. Delivers humanized, knockin, and conditional knockout models and inducible, spatiotemporal gene control using RMCE, FLEx, SSR, TET system, and homologous recombination, enabling gene insertions, deletions, inversions and to predict the success of new therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genoway company profile →
Hain Lifescience
HQ: Germany
Website
- Description: Provider of in-vitro diagnostics as a manufacturer and distributor, located in Nehren.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hain Lifescience company profile →
Astute Medical
HQ: United States
Website
- Description: Provider of diagnostic solutions for high-risk medical conditions via identification and validation of protein biomarkers, focused on community and hospital-acquired acute conditions needing rapid diagnosis and risk assessment. Products include BIOFIRE FILMARRAY Torch, VITEK MS, VIDAS BRAHMS PCT, and BACT/ALERT VIRTUO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Astute Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 10x Genomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 10x Genomics
2.2 - Growth funds investing in similar companies to 10x Genomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 10x Genomics
4.2 - Public trading comparable groups for 10x Genomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →